Cargando…
A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
We describe a phase III trial on 200 patients with end stage squamous cell carcinoma of the head and neck. The patients were randomised to one of four treatment arms: cisplatinum alone, methotrexate alone, cisplatinum + 5-FU and cisplatinum + methotrexate. There was no significant difference in the...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971415/ https://www.ncbi.nlm.nih.gov/pubmed/2178667 |
Ejemplares similares
-
Ototoxicity of cisplatinum.
por: Brock, P., et al.
Publicado: (1991) -
Combined Cisplatinum and Laser Thermal Therapy for Palliation of Recurrent Head and Neck Tumors
por: Paiva, Marcos B., et al.
Publicado: (2000) -
Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum.
por: Cooke, L. D., et al.
Publicado: (1990) -
Ototoxicity of cisplatinum in children and adolescents.
por: Skinner, R., et al.
Publicado: (1990) -
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients
por: Hu, Guofang, et al.
Publicado: (2016)